Article info

Download PDFPDF

Original research
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma

Authors

  • Hirokazu Matsushita Department of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Cancer Immunology Data Multi-level Integration Unit, Medical Science Innovation Hub Program, RIKEN, Chuo-ku, Tokyo, Japan Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan Division of Cancer Immunogenomics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan PubMed articlesGoogle scholar articles
  • Kosei Hasegawa Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan PubMed articlesGoogle scholar articles
  • Katsutoshi Oda Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Shogo Yamamoto Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Kayo Asada Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Takahiro Karasaki Department of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Cancer Immunology Data Multi-level Integration Unit, Medical Science Innovation Hub Program, RIKEN, Chuo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Akira Yabuno Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan PubMed articlesGoogle scholar articles
  • Akira Nishijima Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Takahide Nejo Department of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Yukari Kobayashi Department of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Sho Sato Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan PubMed articlesGoogle scholar articles
  • Yuji Ikeda Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Manami Miyai Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan PubMed articlesGoogle scholar articles
  • Yusuke Takahashi Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan PubMed articlesGoogle scholar articles
  • Rui Yamaguchi Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan Division of Cancer Informatics, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan PubMed articlesGoogle scholar articles
  • Keiichi Fujiwara Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan PubMed articlesGoogle scholar articles
  • Hiroyuki Aburatani Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Meguro-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  • Kazuhiro Kakimi Department of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan Cancer Immunology Data Multi-level Integration Unit, Medical Science Innovation Hub Program, RIKEN, Chuo-ku, Tokyo, Japan PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Hirokazu Matsushita; h.matsushita{at}aichi-cc.jp; Dr Kosei Hasegawa; koseih{at}saitama-med.ac.jp
View Full Text

Citation

Matsushita H, Hasegawa K, Oda K, et al
Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma

Publication history

  • Accepted April 7, 2020
  • First published May 26, 2020.
Online issue publication 
May 26, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.